Non-Invasive
Simple urine sample — no blood draw required. The same specimen type that physicians already collect and patients are familiar with.
Detecting cardiovascular risk.
Years earlier.
Teucer Diagnostics is developing a non-invasive test that identifies vascular injury before it is detectable by standard screening tools.
Learn MoreThe Challenge
Silent Disease
Cardiovascular disease is the leading cause of death worldwide — yet most cases are preventable with early intervention. Unfortunately, by the time current screening tools identify risk, significant vascular damage has already occurred — the window for prevention is closing before physicians even know to look.
Our Mission
Enabling Detection
Teucer Diagnostics is building tools that detect cardiovascular and renal risk at the earliest possible stage — using a simple urine sample. Our technology is designed to identify patients who are at risk years before conventional tests flag potential issues, enabling earlier intervention when it can make the greatest difference.
Our Approach
A New Window Into Vascular Health
Our proprietary assay measures a molecular signal in urine that reflects early injury along the cardiorenal axis — the interconnected biology of the heart and kidneys that is increasingly recognized as central to cardiovascular health. Unlike current screening tools, which detect damage after it has progressed, our approach identifies risk at the point when preventive intervention can be most effective.
Earlier Signal
Detects risk years before current standard-of-care screening tools. Identifies vascular injury at a stage when prevention is most effective.
Clinically Integrated
Fits into existing clinical workflows without requiring new equipment or protocols. Results reported as a clear, actionable risk classification.
The Team
Leadership & Governance
Teucer is built by experienced operators and physician-scientists with deep expertise in clinical medicine, diagnostic technology, and commercial strategy.
Leadership
Chief Executive Officer
Evan Luxon
Medtech founder of Accuryn, Osteoboost, and Centese — served as CEO from concept through commercialization. Former FDA Medical Device Fellow with MS in biomedical engineering from Johns Hopkins and MS in mechanical engineering from Stanford.
Scientific Co-Founders
American University of Beirut
Kamal Badr, MD
Nephrologist with a career in clinical medicine at Vanderbilt and Emory. Co-inventor of the technology and founding director of the Vascular Medicine Program at the American University of Beirut.
Johns Hopkins University
Joao Lima, MD
Cardiovascular researcher at Johns Hopkins University. Principal Investigator of the Multi-Ethnic Study of Atherosclerosis (MESA), a landmark longitudinal cardiovascular outcomes study.
Society of Thoracic Surgeons
Robert Habib, PhD
Biomedical engineer and Vice President of the Society of Thoracic Surgeons (STS). Heads the STS Research and Analytic Center, bringing deep expertise in clinical outcomes research.
American University of Beirut
Assaad Eid, DSc, MBA
Chair of Anatomy, Cell Biology, and Physiological Sciences at the American University of Beirut. The Teucer Diagnostics assay was first designed and developed in his laboratory.
Board of Directors
Evan Luxon
Chief Executive Officer, Teucer Diagnostics
Kamal Badr, MD
Co-Founder · American University of Beirut
Joao Lima, MD
Co-Founder · Johns Hopkins University
Robert Habib, PhD
Co-Founder · Society of Thoracic Surgeons
Assaad Eid, DSc, MBA
Co-Founder · American University of Beirut
Yousif Asfour, PhD
Director · American University of Beirut Representative
Tony Chaya, PhD, MBA
Director · Investor Representative
Affiliations & Support
NIH SBIR
Federal Funding
UNMC
Research Partner
AUB
Founding Research
State of Nebraska
State Support
Bio Nebraska
Member
Contact Us
Get in Touch
We welcome inquiries from potential partners, investigators, and investors interested in learning more about Teucer Diagnostics and our mission to enable earlier disease detection.
Location
Omaha, Nebraska